succinobucol

succinobucol

An antioxidant and anti-inflammatory compound belonging to a new class of agents—composite vascular protectants—which also has potential as an anti-diabetic agent.

Mechanism
Succinobucol blocks production of certain inflammatory mediators (e.g., VCAM-1 and MCP-1), which are implicated in atherosclerosis. Succinobucol may reduce or reverse morbidity and mortality of coronary heart disease, as well as the rate of restenosis in stents.
References in periodicals archive ?
Recently the results of a large outcome study have been reported in which succinobucol or placebo was prescribed to patients with the acute coronary syndrome in addition to standard treatment.
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, doubleblind, placebo-controlled trial.
NEW ORLEANS -- Succinobucol, a novel antioxidant with anti-inflammatory properties, achieved a 64% reduction in new-onset diabetes in patients with a recent acute coronary syndrome in the phase III Aggressive Reduction of Inflammation Stops Events (ARISE) trial.
Succinobucol failed to achieve a significant impact on the primary end point, a composite of "hard" atherosclerotic outcomes and the "soft" end points of coronary revascularization and hospitalization for unstable angina, said Dr.
The 6,144 ARISE participants were randomized to 300 mg/day of succinobucol or placebo for an average of 2 years starting shortly after hospitalization for an acute MI or unstable angina.
Consistent with this benefit, succinobucol resulted in a mean 0.
7% with succinobucol, for a significant 19% relative risk reduction.
The 6,144 ARISE participants were randomized to 300 mg/day of succinobucol or placebo for a mean of 2 years starting shortly after hospitalization for an acute MI or unstable angina.
In patients with diabetes at entry, succinobucol resulted in a mean 0.
Succinobucol, a potent lipophilic antioxidant, is the monosuccinic acid ester of probucol.